GHRS Stock Forecast & Price Target

GH Research is viewed positively because GH001 has shown unusually strong phase 2b efficacy in TRD, including a -15.5 point placebo-adjusted MADRS reduction at Day 8, 57.5% remission at Day 8 versus 0% on placebo, and 73% remission at 6 months, supporting a potentially differentiated profile. The investment case is further strengthened by July 2026 FDA confirmation that the CMC package and proprietary aerosol delivery device appear Phase III ready, while pivotal doses have been selected and Phase III initiation remains on track for 2026. Its first-mover intellectual property position, favorable patent outcome in Europe, limited-center trial design, and anticipated YE26 net cash position add regulatory, competitive, and balance-sheet support to the long-term story.

GH Research is exposed to substantial development and regulatory risk, as the FDA could keep the clinical hold on GH001, demand more information before removal, or ultimately reject the Phase III design and pivotal endpoint strategy. Even if the hold is lifted, the registrational study may fail to reproduce earlier efficacy, face unforeseen safety or device-manufacturing issues, or encounter a deteriorating clinical profile in Phase III relative to Phase II, while GH001 also faces DEA rescheduling uncertainty and competitive pressure from other TRD therapies. Commercially, the company may struggle to secure financing for Phase III or launch, and even an approved product could see slower-than-expected real-world adoption because of its administration method and the need for multiple treatments in a session.